{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T21:26:10Z","timestamp":1773437170951,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.ejmech.2014.05.039","type":"journal-article","created":{"date-parts":[[2014,5,13]],"date-time":"2014-05-13T21:02:46Z","timestamp":1400014966000},"page":"47-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Carbonic anhydrase inhibitors. Synthesis of a novel series of 5-substituted 2,4-dichlorobenzenesulfonamides and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII"],"prefix":"10.1016","volume":"82","author":[{"given":"Jaros\u0142aw","family":"S\u0142awi\u0144ski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aneta","family":"Pogorzelska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata","family":"\u017bo\u0142nowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamil","family":"Bro\u017cewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Vullo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudiu T.","family":"Supuran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2014.05.039_bib1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejca.2007.07.034","article-title":"Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT)","volume":"44","author":"Booth","year":"2008","journal-title":"EJC"},{"key":"10.1016\/j.ejmech.2014.05.039_bib2","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nrd3554","article-title":"Interfering with pH regulation in tumours as a therapeutic strategy","volume":"10","author":"Neri","year":"2011","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.ejmech.2014.05.039_bib3","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrd2467","article-title":"Carbonic anhydrases: novel therapeutic applications for inhibitors and activators","volume":"7","author":"Supuran","year":"2008","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.ejmech.2014.05.039_bib4","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1021\/jm031057+","article-title":"Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides","volume":"47","author":"Vullo","year":"2004","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2014.05.039_bib5","doi-asserted-by":"crossref","first-page":"7860","DOI":"10.1021\/jm050483n","article-title":"Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors","volume":"48","author":"Nishimori","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2014.05.039_bib6","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1021\/jm0612057","article-title":"Carbonic anhydrase inhibitors. DNA cloning, characterization and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors","volume":"50","author":"Nishimori","year":"2007","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2014.05.039_bib7","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.bmcl.2004.12.052","article-title":"Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides","volume":"15","author":"Vullo","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2014.05.039_bib8","series-title":"Carbonic Anhydrase \u2013 its Inhibitors and Activators","first-page":"25","article-title":"Acatalytic CAs: carbonic anhydrase-related proteins","author":"Nishimori","year":"2004"},{"key":"10.1016\/j.ejmech.2014.05.039_bib9","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0960-894X(03)00091-X","article-title":"Carbonic anhydrase inhibitors. Inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides","volume":"13","author":"Vullo","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2014.05.039_bib10","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.bmcl.2004.12.053","article-title":"Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides \u2013 a new target for the design of antitumor and antiglaucoma drugs?","volume":"15","author":"Vullo","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2014.05.039_bib11","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1074\/jbc.M308984200","article-title":"Characterization of CA XIII, a novel member of the carbonic anhydrase isozyme family","volume":"279","author":"Lehtonen","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2014.05.039_bib12","doi-asserted-by":"crossref","first-page":"8329","DOI":"10.1021\/ja061574s","article-title":"Carbonic anhydrase inhibitors: X-ray and molecular modeling study for the interaction of a fluorescent antitumor sulfonamide with isozyme II and IX","volume":"128","author":"Alterio","year":"2006","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2014.05.039_bib13","first-page":"2788","article-title":"Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and putative helix-loop-helix DNA binding segment","volume":"9","author":"Pastorek","year":"1994","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2014.05.039_bib14","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1006\/geno.1996.0223","article-title":"Human MN\/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships","volume":"33","author":"Opavsky","year":"1996","journal-title":"Genomics"},{"key":"10.1016\/j.ejmech.2014.05.039_bib15","doi-asserted-by":"crossref","first-page":"7608","DOI":"10.1073\/pnas.95.13.7608","article-title":"Human carbonic anhydrase XII: cDNA cloning, expression and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cancers","volume":"95","author":"T\u00fcreci","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2014.05.039_bib16","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1517\/13543776.14.5.667","article-title":"Modulation of carbonic anhydrase activity and its applications in therapy","volume":"14","author":"Scozzafava","year":"2004","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2014.05.039_bib17","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/med.10025","article-title":"Carbonic anhydrase inhibitors","volume":"23","author":"Supuran","year":"2003","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2014.05.039_bib18","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0014-4827(03)00351-3","article-title":"Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with \u03b2-catenin","volume":"290","author":"Svastova","year":"2003","journal-title":"Exp. Cell. Res."},{"key":"10.1016\/j.ejmech.2014.05.039_bib19","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0065-2423(06)42005-9","article-title":"Tumor-associated carbonic anhydrases and their clinical significance","volume":"42","author":"Pastorekova","year":"2006","journal-title":"Adv. Clin. Chem."},{"key":"10.1016\/j.ejmech.2014.05.039_bib20","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10555-007-9064-0","article-title":"Regulation of tumor pH and the role of carbonic anhydrase 9","volume":"26","author":"Swietach","year":"2007","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ejmech.2014.05.039_bib21","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.febslet.2004.10.043","article-title":"Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH","volume":"577","author":"Svastova","year":"2004","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejmech.2014.05.039_bib22","doi-asserted-by":"crossref","first-page":"84","DOI":"10.18632\/oncotarget.422","article-title":"Recent developments in targeting carbonic anhydrase IX for cancer therapeutics","volume":"3","author":"McDonald","year":"2012","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2014.05.039_bib23","doi-asserted-by":"crossref","first-page":"6160","DOI":"10.1158\/0008-5472.CAN-03-2224","article-title":"Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion","volume":"64","author":"Robertson","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2014.05.039_bib24","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/med.20112","article-title":"Carbonic anhydrase IX: a new drugable target for the design of antitumor agents","volume":"28","author":"Winum","year":"2008","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2014.05.039_bib25","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/146164a0","article-title":"Sulphanilamide as a specific carbonic anhydrase inhibitor","volume":"146","author":"Mann","year":"1940","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2014.05.039_bib26","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1146\/annurev.pa.16.040176.001521","article-title":"Relations between structure and biological activity of sulfonamides","volume":"16","author":"Maren","year":"1976","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejmech.2014.05.039_bib27","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1152\/physrev.1967.47.4.595","article-title":"Carbonic anhydrase: chemistry, physiology and inhibition","volume":"47","author":"Maren","year":"1967","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejmech.2014.05.039_bib28","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1517\/13543776.10.5.575","article-title":"Carbonic anhydrase inhibitors and their therapeutic potential","volume":"10","author":"Supuran","year":"2000","journal-title":"Exp. Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2014.05.039_bib29","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.287.5460.1960","article-title":"Drug discovery: a historical perspective","volume":"287","author":"Drew","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2014.05.039_bib30","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1517\/13543776.2013.798648","article-title":"Anticancer carbonic anhydrase inhibitors: a patent review (2008\u20132013)","volume":"23","author":"Monti","year":"2013","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2014.05.039_bib31","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0968-0896(00)00288-1","article-title":"Carbonic anhydrase inhibitors: sulfonamides as antitumor agents?","volume":"9","author":"Supuran","year":"2001","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2014.05.039_bib32","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1517\/13543784.12.2.283","article-title":"Indisulam: an anticancer sulfonamide in clinical development","volume":"12","author":"Supuran","year":"2003","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ejmech.2014.05.039_bib33","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.bmcl.2003.09.062","article-title":"Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX","volume":"14","author":"Abbate","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2014.05.039_bib34","doi-asserted-by":"crossref","first-page":"4862","DOI":"10.1016\/j.bmcl.2005.08.048","article-title":"Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides","volume":"15","author":"\u00d6zensoy","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2014.05.039_bib35","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1021\/jm0494826","article-title":"Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating hydrazino moieties","volume":"48","author":"Winum","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2014.05.039_bib36","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1021\/jm101541x","article-title":"Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IC and show antimetastatic activity in a model of breast cancer metastasis","volume":"54","author":"Pacchiano","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2014.05.039_bib37","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1021\/jm021123s","article-title":"Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX by halogenosulfanilamide and halogenophenylaminobenzolamide derivatives","volume":"46","author":"Ilies","year":"2003","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2014.05.039_bib38","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1158\/0008-5472.CAN-10-4261","article-title":"Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors","volume":"17","author":"Lou","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2014.05.039_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/onc.2012.550","article-title":"Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche","author":"Lock","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2014.05.039_bib40","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1016\/j.bmcl.2006.06.064","article-title":"Carbonic anhydrase inhibitors. Inhibition of the cytosolic human isozymes I and II, and the transmembrane, tumor-associated isozymes IX and XII with substituted aromatic sulfonamides activatable in hypoxic tumors","volume":"16","author":"S\u0105czewski","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2014.05.039_bib41","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1080\/14756360600648146","article-title":"Carbonic anhydrase inhibitors. Selective inhibition of human tumor-associated isozymes IX and XII and cytosolic isozymes I and II with some substituted-2-mercapto-benzenesulfonamides","volume":"21","author":"S\u0105czewski","year":"2006","journal-title":"J.\u00a0Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2014.05.039_bib42","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1016\/j.bmc.2008.01.034","article-title":"Carbonic anhydrase inhibitors: inhibition of human cytosolic isozymes I and II and tumor-associated isozymes IX and XII with S-substituted 4-chloro-2-mercapto-5-methyl-benzenesulfonamides","volume":"16","author":"S\u0105czewski","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2014.05.039_bib43","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1021\/jm00311a012","article-title":"Diuretics. 4-Substituted 3-sulfamoylbenzoic acid hydrazides","volume":"11","author":"Hoefle","year":"1968","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2014.05.039_bib44","first-page":"141","article-title":"Pochodne kwasu 4-chloro-5-sulfoamoilobenzoesowego. 8. Synteza i w\u0142a\u015bciwo\u015bci diuretyczne pochodnych pirazolo [3,2-b] chinazoliny i 1-benzoilopirazolu","volume":"41","author":"Pomarnacka","year":"1984","journal-title":"Acta Pol. Pharm."},{"key":"10.1016\/j.ejmech.2014.05.039_bib45","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00706-012-0732-6","article-title":"Synthesis and in\u00a0vitro activity of novel 2-(benzylthio)-4-chloro-5-(1,3,4-oxadiazol-2-yl)benzenesulfonamide derivatives","volume":"143","author":"Bro\u017cewicz","year":"2012","journal-title":"Monatsh. Chem."},{"key":"10.1016\/j.ejmech.2014.05.039_bib46","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1016\/S0021-9258(18)62326-9","article-title":"The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C","volume":"246","author":"Khalifah","year":"1971","journal-title":"J.\u00a0Biol. Med."},{"key":"10.1016\/j.ejmech.2014.05.039_bib47","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1021\/jm031079w","article-title":"Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX","volume":"47","author":"Casey","year":"2004","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2014.05.039_bib48","first-page":"589","article-title":"Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay","volume":"48","author":"Alley","year":"1988","journal-title":"Cancer Res."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352341400453X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352341400453X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T14:40:46Z","timestamp":1648996846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352341400453X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":48,"alternative-id":["S022352341400453X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2014.05.039","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Carbonic anhydrase inhibitors. Synthesis of a novel series of 5-substituted 2,4-dichlorobenzenesulfonamides and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2014.05.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}